이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ainos 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chun-Hsien Tsai

최고 경영자

US$1.3m

총 보상

CEO 급여 비율	7.5%
CEO 임기	3.3yrs
CEO 소유권	4.2%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Sep 30

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Aug 24

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Aug 15

CEO 보상 분석

Chun-Hsien Tsai 의 보수는 Ainos 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$1m	US$96k	-US$14m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$4m	US$100k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$82k	US$45k	-US$4m

보상 대 시장: Chun-Hsien 의 총 보상 ($USD 1.29M )은 US 시장( $USD 683.56K ).

보상과 수익: Chun-Hsien 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chun-Hsien Tsai (54 yo)

3.3yrs

테뉴어

US$1,285,023

보상

Mr. Chun-Hsien Tsai has been Chairman of Board, President and Chief Executive Officer at Ainos, Inc. since April 15, 2021 and served as its Chief Financial Officer since April 15, 2021 until August 11, 202...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chun-Hsien Tsai	Chairman of Board	3.3yrs	US$1.29m	4.25% $ 259.6k
Yao-Chung Chiang	Independent Director	3.3yrs	US$178.25k	0.84% $ 51.6k
Pao-Sheng Wei	Independent Director	2.1yrs	US$184.25k	0.81% $ 49.8k
Wen-Han Chang	Independent Director	3.3yrs	US$182.75k	1.63% $ 99.9k
Ting-Chuan Lee	Director	3.3yrs	US$162.25k	1.24% $ 76.0k
Chun-Jung Tsai	Director	3.3yrs	US$162.25k	1.11% $ 67.9k
Chung-Yi Tsai	Director	3.3yrs	US$174.25k	0.81% $ 49.8k

3.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: AIMD 의 이사회는 경험(평균 재직 기간 3.2 년)으로 간주됩니다.

Ainos 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Recent updates

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.63 loss in 1Q 2023)

New major risk - Shareholder dilution

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Full year 2023 earnings released: US$3.36 loss per share (vs US$5.14 loss in FY 2022)

Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms

New minor risk - Shareholder dilution

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell

Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary

Less than half of directors are independent

Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Ainos, Inc., Annual General Meeting, Dec 08, 2023

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.20 loss in 2Q 2022)

Staff of Nasdaq Determines Ainos is Eligible for an Additional 180 Calendar Day Period, or Until January 2, 2024, to Regain Compliance with Its Minimum Bid Price Requirement

Ainos, Inc. Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20 Million Revenue Target

Ainos, Inc. Announces Chief Financial Officer Changes

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.22 loss in 1Q 2022)

Full year 2022 earnings released: US$1.03 loss per share (vs US$0.52 loss in FY 2021)

Ainos Receives Non-Compliance Notice From Nasdaq

Ainos, Inc Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Third quarter 2022 earnings released: US$0.51 loss per share (vs US$0.12 loss in 3Q 2021)

Less than half of directors are independent

Ainos, Inc. Pursues Licensing Partners to Accelerate Five Candidates of Its Low-Dose Oral Interferon Formulation Veldona to Phase 3 Trials and Commercialization

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-Dose Oral Interferon Formulation Against New Variant Virus - Omicron

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Second quarter 2022 earnings released: US$0.014 loss per share (vs US$0.09 loss in 2Q 2021)

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Ainos, Inc. has completed a Composite Units Offering in the amount of $3.315 million.

Less than half of directors are independent

Ainos Announces Positive Results from Preclinical Studies of Its Low-Dose Oral Interferon Formulation Against Covid-19

Ainos, Inc. Announces Executive Changes

Ainos, Inc. announced delayed 10-Q filing

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령